INSMED INC Cash and Cash Equivalents
INSMED INC (INSM) had Cash and Cash Equivalents of $544.76 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $544.76M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $582.19M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $510.44M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $334.76M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $544.76M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $582.19M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $510.44M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $334.76M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.28B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $403.25M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $555.03M 10-K · filed 2026-02-19 |
| 2024-09-30 | $461.45M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.25B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $595.73M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $482.37M 10-K · filed 2025-02-20 |
| 2023-09-30 | $487.11M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $612.88M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $968.91M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.07B 10-K · filed 2024-02-22 |
| 2022-09-30 | $414.63M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $416.08M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $515.70M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $716.78M 10-K · filed 2023-02-23 |
| 2021-09-30 | $846.56M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $928.33M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $409.75M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $532.76M 10-K · filed 2022-02-17 |
| 2020-09-30 | $588.75M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $641.91M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $428.94M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $487.43M 10-K · filed 2021-02-25 |
| 2019-09-30 | $535.63M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $601.26M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $420.23M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $495.07M 10-K · filed 2020-02-25 |
| 2018-09-30 | $567.57M 10-Q · filed 2018-10-30 |
| 2018-06-30 | $634.33M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $686.58M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $381.17M 10-K · filed 2019-02-22 |
| 2017-09-30 | $430.68M 10-Q · filed 2018-10-30 |
| 2017-06-30 | $91.06M 10-Q · filed 2018-08-02 |
| 2017-03-31 | $125.84M 10-Q · filed 2018-05-02 |
| 2016-12-31 | $162.59M 10-K · filed 2019-02-22 |
| 2016-09-30 | $200.52M 10-Q · filed 2017-11-02 |
| 2016-06-30 | $223.11M 10-Q · filed 2017-08-03 |
| 2016-03-31 | $252.87M 10-Q · filed 2017-05-03 |
| 2015-12-31 | $282.88M 10-K · filed 2019-02-22 |
| 2015-09-30 | $310.97M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $335.03M 10-Q · filed 2016-08-04 |
| 2015-03-31 | $134.55M 10-Q · filed 2016-05-05 |
| 2014-12-31 | $159.23M 10-K · filed 2018-02-23 |
| 2014-09-30 | $167.31M 10-Q · filed 2015-11-06 |
| 2014-06-30 | $82.70M 10-Q · filed 2015-08-06 |
| 2014-03-31 | $101.25M 10-Q · filed 2015-05-07 |
| 2013-12-31 | $113.89M 10-K · filed 2017-02-23 |
| 2013-09-30 | $128.03M 10-Q · filed 2014-11-06 |
| 2013-06-30 | $74.59M 10-Q · filed 2014-08-06 |
| 2013-03-31 | $79.43M 10-Q · filed 2014-05-08 |
| 2012-12-31 | $90.78M 10-K · filed 2016-02-25 |
| 2012-09-30 | $44.99M 10-Q · filed 2013-11-05 |
| 2012-06-30 | $28.57M 10-Q · filed 2013-08-06 |
| 2012-03-31 | $22.04M 10-Q · filed 2013-05-07 |
| 2011-12-31 | $14.85M 10-K · filed 2015-02-27 |
| 2011-09-30 | $10.45M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $9.84M 10-Q/A · filed 2011-08-08 |
| 2010-12-31 | $10.74M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |